Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hematologic Malignancies

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2024-055
    NCT ID
    • NCT06507306
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator
    • Image of Jay Yang , M.D.
      Jay
      Yang, M.D.
      Oncology - Hematology, Oncology - Medical View Profile

    Objective:

    Primary Objective:

    • Part 1: To determine the safety, tolerability, and RP2D of KQB198 as monotherapy and in combination with dasatinib
    • Part 2, Cohort A: To evaluate the efficacy of KQB198 in combination with dasatinib and determine the OBD
    • Part 2, Cohort B: To evaluate the efficacy of KQB198 monotherapy and determine the OBD

    Secondary Objective:

    • Part 1: To evaluate the efficacy of KQB198 as monotherapy and in combination with dasatinib
    • Part 2, Cohorts A and B: To evaluate the efficacy of KQB198 monotherapy and in combination with dasatinib
    • All Parts: To evaluate the safety and tolerability of KQB198 as monotherapy and in combination with dasatinib
    • All Parts: To evaluate the plasma pharmacokinetics (PK) of KQB198 alone or KQB198 and dasatinib when administered in combination
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 1-800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 1-800-527-6266